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Summary
Background The gold standard endpoint in clinical trials of chemotherapy and radiotherapy for lung cancer is overall 
survival. Although reliable and simple to measure, this endpoint takes years to observe. Surrogate endpoints that 
would enable earlier assessments of treatment eﬀ ects would be useful. We assessed the correlations between potential 
surrogate endpoints and overall survival at individual and trial levels. 
Methods We analysed individual patients’ data from 15 071 patients involved in 60 randomised clinical trials that were 
assessed in six meta-analyses. Two meta-analyses were of adjuvant chemotherapy in non-small-cell lung cancer, three 
were of sequential or concurrent chemotherapy, and one was of modiﬁ ed radiotherapy in locally advanced lung 
cancer. We investigated disease-free survival (DFS) or progression-free survival (PFS), deﬁ ned as the time from 
randomisation to local or distant relapse or death, and locoregional control, deﬁ ned as the time to the ﬁ rst local event, 
as potential surrogate endpoints. At the individual level we calculated the squared correlations between distributions 
of these three endpoints and overall survival, and at the trial level we calculated the squared correlation between 
treatment eﬀ ects for endpoints. 
Findings In trials of adjuvant chemotherapy, correlations between DFS and overall survival were very good at the 
individual level (²=0·83, 95% CI 0·83–0·83 in trials without radiotherapy, and 0·87, 0·87–0·87 in trials with 
radiotherapy) and excellent at trial level (R²=0·92, 95% CI 0·88–0·95 in trials without radiotherapy and 0·99, 
0·98–1·00 in trials with radiotherapy). In studies of locally advanced disease, correlations between PFS and overall 
survival were very good at the individual level (² range 0·77–0·85, dependent on the regimen being assessed) and 
trial level (R² range 0·89–0·97). In studies with data on locoregional control, individual-level correlations were good 
(²=0·71, 95% CI 0·71–0·71 for concurrent chemotherapy and ²=0·61, 0·61–0·61 for modiﬁ ed vs standard 
radiotherapy) and trial-level correlations very good (R²=0·85, 95% CI 0·77–0·92 for concurrent chemotherapy and 
R²=0·95, 0·91–0·98 for modiﬁ ed vs standard radiotherapy).
Interpretation We found a high level of evidence that DFS is a valid surrogate endpoint for overall survival in studies 
of adjuvant chemotherapy involving patients with non-small-cell lung cancers, and PFS in those of chemotherapy and 
radiotherapy for patients with locally advanced lung cancers. Extrapolation to targeted agents, however, is not 
automatically warranted. 
Funding Programme Hospitalier de Recherche Clinique, Ligue Nationale Contre le Cancer, British Medical Research 
Council, Sanoﬁ -Aventis.
Introduction 
Worldwide, around 1·6 million new cases of lung cancer 
are diagnosed annually, which accounts for 13% of all 
diagnosed cancers and comprised, with 1·4 million 
deaths, 18% of cancer deaths in 2008. Lung cancer is the 
leading cause of cancer deaths in male patients.1 80–85% 
of tumours are non-small-cell lung cancers (NSCLCs),2 
which include adenocarcinomas, squamous-cell and 
large-cell carcinomas. The remaining 15–20% are small-
cell lung cancers (SCLCs). Estimated 5-year survival in 
NSCLC is only 16%.3 Although surgery is generally 
viewed as the optimum treatment, only about 30% of 
patients qualify for potentially curative resection.4 A 
further 20%, mainly those presenting with locally 
advanced disease, undergo radical thoracic radiotherapy, 
with or without chemotherapy. The remaining 50% of 
patients, most of whom have late-stage or metastatic 
disease, generally receive palliative treatments.
The gold standard endpoint in randomised clinical 
trials of lung cancer is overall survival because it is 
simple to measure, easy to interpret, and measurement 
is unbiased. Some of the disadvantages of this endpoint 
are the need for long-term follow-up and large numbers 
of patients, the eﬀ ect of successive treatment lines that 
might prolong survival, and the risk of non-cancer 
deaths rising with increasing time. Use of a surrogate 
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endpoint at an earlier stage in clinical trials would speed 
up assessment of treatments and might reduce the cost 
of drug development. Between December, 1992, and 
July, 2010, the Food and Drug Administration granted 
accelerated approval for 35 oncology products on the 
basis of surrogate endpoints, such as disease-free 
survival ([DFS] eg, anastrozole in breast cancer) and 
progression-free survival ([PFS] eg, panitumumab in 
advanced colon cancer).5 In Europe in 2009, the 
European Medicines Agency approved geﬁ nitib as ﬁ rst-
line treatment in patients with locally advanced or 
metastatic EGFR-mutation-positive NSCLC, and 
extended the licence of erlotinib for this treatment in 
2011, both on the basis of PFS.6,7 Additionally, multiple 
second-line treatment options have become available, 
which encourages use of intermediate endpoints in 
studies of NSCLC.8
To be suitable, surrogate endpoints should predict 
overall survival, and the eﬀ ect of treatments on the 
surrogate endpoints should predict their eﬀ ects on 
overall survival in meta-analyses of individual patients’ 
data.9 We have analysed trial data from ﬁ ve meta-analyses 
of individual patients’ data by the NSCLC Meta-analyses 
Collaborative Group10–13 and from one by the MAR-LC 
Collaborative Group14 to assess the use of DFS, PFS, and 
locoregional control as surrogate endpoints for overall 
survival. 
Methods
We assessed endpoints according to the following 
preplanned objectives: assess DFS as a surrogate 
endpoint for overall survival in patients with resectable 
NSCLC in trials studying the eﬀ ect of adjuvant 
chemotherapy; assess PFS as a surrogate for overall 
survival in trials of chemotherapy and radiotherapy in 
patients with locally advanced lung cancer; and appraise 
time to locoregional control as a surrogate for overall 
survival in trials of radiotherapy or concurrent 
radiochemotherapy in locally advanced lung cancer. All 
analyses presented used the statistical methods described 
in the study protocol. All trials from the meta-analyses 
with available event data were included (appendix). All 
randomised patients were analysed according to 
intention to treat. 
Endpoint deﬁ nitions
In all trials, data on events had been collected 
prospectively. Overall survival was deﬁ ned as time from 
randomisation to death, irrespective of cause. Patients 
still alive at the last visit were censored as the date of last 
follow-up. DFS in patients suitable for surgery was 
deﬁ ned as the time from randomisation to the ﬁ rst event 
(locoregional or distant recurrence or death from any 
cause). Patients without documented evidence of an 
event were censored at the date of last follow-up. PFS in 
patients unsuitable for surgery was deﬁ ned as the time 
from randomisation to the ﬁ rst event (locoregional or 
distant progression or death). Patients who had no 
documented evidence of events were censored at the date 
of last follow-up. Locoregional control was deﬁ ned as the 
time from randomisation to the ﬁ rst locoregional event. 
Patients with distant progression, who died or who had 
no documented evidence of distant progression or death 
were censored at the date of distant progression or last 
follow-up.
Statistical analysis
Statistical analyses were done with SAS (version 9.2). 
The rank correlation coeﬃ  cient  between distributions 
of the candidate surrogate endpoints and overall survival 
at the individual level was assessed with a bivariate 
survival model that takes censoring into account.15 The 
trial-level correlations between treatment eﬀ ects (log 
hazard ratios) on the candidate surrogate endpoints and 
overall survival were quantiﬁ ed through a linear 
regression model,16 weighted by trial size. In trials of 
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Number of 
patients (trials)*
Disease-free or progression-free 
survival
Overall survival
Number of 
events
Median (range) survival Number of 
deaths
Median (range) survival
Adjuvant therapy
Chemotherapy vs no chemotherapy 5379 (17) 2525 6·4 years (0–16·7) 2163  8·2 years (0–16·7) 
Radiotherapy+chemotherapy vs radiotherapy alone 2247 (7) 1673 1·6 years (0–22·2) 1566  2·5 years (0–22·2) 
Locally advanced disease
Radiotherapy+sequential chemotherapy vs 
radiotherapy alone
1458 (8) 1375 7·9 mo nths (0–213·6) 1333 11·7 months (0–213·6) 
Radiotherapy+concurrent chemotherapy vs 
radiotherapy alone
2552 (15) 2391 8·1 months (0–189·6) 2305 14·1 months (0–189·6) 
Radiotherapy+sequential chemotherapy vs 
radiotherapy+concurrent chemotherapy
1201 (6) 1094 8·3 months (0–134·4) 1065 14·6 months (0–134·4) 
Modiﬁ ed radiotherapy vs standard radiotherapy 2685 (12) 2562 9·1 months (0–171·6) 2471 15·0 months (0–171·6) 
*In multiarm trials, control patients and treatment comparisons are counted twice; the total number of unique patients is 15 071 and of unique trials is 60.
Table 1: Description of trials by setting
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adjuvant chemotherapy, correlations between treatment 
eﬀ ects on 3-year DFS and 5-year overall survival (with 
censoring of all patients at 3 years and 5 years) were 
assessed.17 In patients with locally advanced disease, 
correlations between 2-year PFS and 5-year overall 
survival were assessed.18 A sensitivity analysis assessed 
diﬀ erent cutoﬀ  points.
The squared correlation coeﬃ  cients or coeﬃ  cients of 
determination—ie, ² at the individual level and R² at the 
trial level—were calculated to investigate the amount of 
variation explained by the surrogate. The candidate 
surrogate endpoints were deemed acceptable only if both 
correlation coeﬃ  cients were close to 1·00. We classiﬁ ed 
squared correlation values higher than 0·9 as excellent,19 
higher than 0·75 as very good, higher than 0·5 as good, 
higher than 0·25 as moderate, and equal to or lower than 
0·25 as poor. 
The surrogate threshold eﬀ ect was calculated, and was 
deﬁ ned as the minimum treatment eﬀ ect on the 
surrogate that would be necessary to predict a non-zero 
eﬀ ect on overall survival.20 A future trial would require an 
upper limit of the CI for the estimated surrogate 
treatment eﬀ ect to fall below the surrogate threshold 
eﬀ ect to predict a non-zero eﬀ ect on overall survival. The 
Kaplan-Meier method was used to calculate curves for 
DFS and overall survival.
For each meta-analysis, we used a leave-one-out cross-
validation approach to assess the prediction accuracy of 
the surrogate model.18 Each trial was left out once and the 
linear model, weighted by trial size, was rebuilt with the 
other trials. This model was then applied to the left-out 
trial and a 95% prediction interval was calculated to 
compare the predicted and observed treatment eﬀ ect on 
overall survival.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. AM, J-PP, and SM had full access to 
all the raw data. The corresponding author had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
This analysis is based on individual data for 15 071 patients 
in 60 randomised trials with long-term follow-up that 
were included in six meta-analyses (table 1).11–14 
In the adjuvant setting, DFS data were available for 
24 trials involving 7626 patients and investigating surgery 
compared with postoperative chemotherapy or no 
postoperative chemotherapy (median follow-up 
5·7 years), or surgery plus postoperative chemotherapy 
and radiotherapy compared with surgery plus 
radiotherapy alone (median follow-up 6·4 years; table 1, 
appendix). Worse median DFS and overall survival in 
trials of postoperative radiotherapy and chemotherapy 
(table 1) reﬂ ected the poorer outlook of patients than in 
trials of chemotherapy alone. 
In the locally advanced setting, PFS data were available 
for 29 chemotherapy trials involving 5211 patients. The 
studies assessed radiotherapy with or without concurrent 
(median follow-up 6·8 years) or sequential chemotherapy 
(median follow-up 5·2 years), or did a head-to-head 
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Figure 1: Kaplan-Meier curves of DFS and OS in assessment of adjuvant chemotherapy for non-small-cell lung 
cancers
(A) Chemotherapy vs no chemotherapy. (B) Radiotherapy+chemotherapy vs radiotherapy alone. OS=overall 
survival. CT=chemotherapy. DFS=disease-free survival. RT=radiotherapy.
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comparison of radiotherapy plus sequential chemo-
therapy versus radiotherapy plus concurrent chemo-
therapy (median follow-up 6·1 years; table 1, appendix). 
Among these studies, locoregional control was assessed 
in 13 trials of radiotherapy with or without concurrent 
chemotherapy that involved 2123 patients. A further 
12 trials were assessed in the locally advanced setting that 
compared standard radiotherapy with hyper fractionated 
or accelerated (modiﬁ ed) radiotherapy in 2685 patients 
(table 1, appendix). All 12 trials had data for PFS, and ten 
had data for locoregional control (2079 patients). Two of 
the trials enrolled only patients with SCLCs and the rest 
those with NSCLCs. The median follow-up time was 
8·6 years. Cumulative percentages of events and 
additional descriptive statistics are shown in the 
appendix. 
A strong association was noted between DFS and 
overall survival in patients with NSCLC who received 
adjuvant chemotherapy with or without radiotherapy 
(²=0·83, 95% CI 0·83–0·83 for chemotherapy vs no 
chemotherapy, and 0·87, 0·87–0·87 for those comparing 
radiotherapy plus chemotherapy vs radiotherapy alone; 
ﬁ gure 1, table 2). The squared correlations between the 
treatment eﬀ ects on DFS and those on overall survival 
were excellent (R²=0·92, 95% CI 0·88–0·95 and 0·99, 
0·98–1·00; table 2). Linear regression showed excellent 
correlation between the treatment eﬀ ects on DFS and 
those on overall survival (ﬁ gure 2, appendix). The 
sensitivity analysis, which aimed to reﬂ ect typical trial 
conditions and to correlate the treatment eﬀ ects 
estimated on DFS at 3 years with those on overall survival 
at 5 years, yielded slightly lower R² values, but these were 
still very good to excellent (0·88, 0·83–0·93 for 
chemotherapy vs no chemotherapy and 0·96, 0·93–0·99 
for radiotherapy plus chemotherapy vs radiotherapy 
alone; table 2). 79% and 84% of DFS events, respectively, 
occurred in the ﬁ rst 3 years (appendix). An exploratory 
analysis with earlier cutoﬀ  times for DFS suggested that 
Figure 2: Correlation between treatment eﬀ ects on disease-free and overall 
survival in the assessment of adjuvant treatment for non-small-cell lung 
cancers
(A) Chemotherapy compared with no chemotherapy. (B) Radiotherapy plus 
chemotherapy compared with radiotherapy alone. Each trial is represented by a 
circle, with a size proportional to the number of patients. A logarithmic scale is 
used on axes. Correlation values are excellent (R2=0·92 and R2=0·99).
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Number of 
patients (trials)
DFS or PFS vs overall survival 3-year DFS or 2-year 
PFS vs 5-year overall 
survival (R2 [95% CI])
Individual level 
(2 [95% CI]) 
Trial level 
(R2 [95% CI])
Adjuvant therapy
Chemotherapy vs no chemotherapy 5379 (17) 0·83 (0·83–0·83) 0·92 (0·88–0·95) 0·88 (0·83–0·93)
Radiotherapy+chemotherapy vs radiotherapy alone 2247 (7) 0·87 (0·87–0·87) 0·99 (0·98–1·00) 0·96 (0·93–0·99)
Locally advanced disease
Radiotherapy+sequential chemotherapy vs radiotherapy alone 1458 (8) 0·77 (0·77–0·77) 0·96 (0·93–0·99) 0·77 (0·63–0·91)
Radiotherapy+concurrent chemotherapy vs radiotherapy alone 2552 (15) 0·85 (0·85–0·85) 0·97 (0·96–0·99) 0·95 (0·92–0·97)
Radiotherapy+sequential chemotherapy vs radiotherapy+concurrent 
chemotherapy
1201 (6) 0·83 (0·83–0·83) 0·89 (0·81–0·97) 0·75 (0·58–0·92)
Modiﬁ ed radiotherapy vs standard radiotherapy 2685 (12) 0·81 (0·81–0·81) 0·96 (0·93–0·98) 0·85 (0·78–0·93)
DFS=disease-free survival. PFS=progression-free survival.
Table 2: Individual and trial-level correlation coeﬃ  cients and sensitivity data for DFS and PFS 
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after only 2 years, treatment eﬀ ects on DFS already 
correlated well with those on overall survival at 5 years 
(appendix). Surrogate threshold eﬀ ects for DFS were 
0·88 for chemotherapy compared with no chemotherapy 
and 0·95 for radiotherapy plus chemotherapy compared 
with radiotherapy alone. 
Survival curves for PFS and overall survival in locally 
advanced disease for radiotherapy plus concurrent 
chemotherapy compared with radiotherapy alone, and 
for modiﬁ ed radiotherapy compared with standard 
radiotherapy are shown in ﬁ gure 3. Very good correlation 
values were noted for locally advanced disease 
(²=0·77–0·85, table 2). Treatment eﬀ ects on PFS 
correlated well from very good to excellent with those on 
overall survival (R²=0·89–0·97, table 2). Linear regression 
conﬁ rmed the strength of the correlation (ﬁ gure 4). In 
the sensitivity analysis, PFS at 2 years correlated 
reasonably strongly at the trial level with overall survival 
(very good to excellent; table 2, appendix). The surrogate 
threshold eﬀ ects for PFS were 0·93 for radiotherapy plus 
sequential chemotherapy compared with radiotherapy 
alone, 0·95 for radiotherapy plus concurrent 
chemotherapy compared with radiotherapy alone, 0·90 
for radiotherapy plus sequential chemo therapy compared 
with radiotherapy plus concurrent chemotherapy, and 
1·00 for modiﬁ ed radiotherapy compared with standard 
radiotherapy.
With respect to locoregional control in the trials of 
radiotherapy plus concurrent chemotherapy compared 
with radiotherapy alone and of modiﬁ ed radiotherapy 
compared with standard radiotherapy, squared 
individual-level correlations with overall survival were 
good (² 0·71, 95% CI 0·71–0·71 and 0·61, 0·61–0·61) 
and the squared treatment-eﬀ ect correlations were very 
good (R² 0·85, 95% CI 0·77–0·92 and 0·95, 0·91–0·98; 
appendix).
The prediction results from the cross-validation 
analyses showed that for DFS in the adjuvant setting, the 
hazard ratios for overall survival fell within the 95% 
prediction intervals in all 17 trials for chemotherapy 
compared with no chemotherapy and in six of seven 
trials of radiotherapy plus chemotherapy compared with 
radiotherapy alone (ﬁ gure 5). For PFS in the locally 
advanced setting, the observed hazard ratio for overall 
survival fell between the limits of the 95% prediction 
intervals in all eight trials for radiotherapy plus sequential 
chemotherapy compared with radiotherapy alone, 14 of 
15 trials of radiotherapy plus concurrent chemotherapy 
compared with radiotherapy alone, all six trials for 
radiotherapy plus sequential chemotherapy compared 
with radiotherapy plus concurrent chemotherapy, and in 
11 of 12 trials of modiﬁ ed radiotherapy compared with 
standard radiotherapy (ﬁ gure 5, appendix). 
Discussion
Our assessment of a large sample of data for patients 
with lung cancer provides high-level evidence that DFS is 
a valid surrogate endpoint for overall survival in studies 
of adjuvant chemotherapy in patients with NSCLC, and 
that PFS is a valid surrogate in assessment of 
chemotherapy and radiotherapy in patients with locally 
advanced disease. DFS and PFS should, therefore, be 
Figure 3: Kaplan-Meier curves of PFS and OS in the treatment of locally advanced disease
(A) Radiotherapy plus concurrent chemoradiotherapy compared with radiotherapy alone in non-small-cell lung 
cancer. (B) Modiﬁ ed radiotherapy compared with standard radiotherapy in non-small-cell and small-cell lung 
cancers. OS=overall survival. RT=radiotherapy. CT=chemotherapy. PFS=progression-free survival.
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considered for use as primary endpoints for 
chemotherapy and radiotherapy trials (panel).
Overall, the correlations for DFS or PFS indicated that 
almost 89–99% of the variation in treatment eﬀ ects on 
overall survival can be explained by eﬀ ects on DFS or 
PFS. The cross-validation results conﬁ rmed the accurate 
prediction of the treatment eﬀ ect on overall survival 
based on the eﬀ ects observed on DFS or PFS. Correlations 
for locoregional control were good at the individual level 
and very good at the trial level, but were a little lower than 
the corresponding values for PFS. Since the number of 
events with locoregional control is always lower than for 
PFS in randomised clinical trials for the same sample 
size and follow-up, the statistical power for the assessment 
of locoregional control will also always be lower. 
The sensitivity analysis strongly suggests that the 
information on DFS and PFS acquired at 3 years and 
2 years, respectively, could be suﬃ  cient to predict the 
5-year eﬀ ect of treatment on overall survival in patients 
with operable and locally advanced tumours. We 
recommend the use of DFS and PFS as time-to-event 
outcomes in randomised clinical trials rather than 
measurement at a speciﬁ c timepoint. 
We used DFS or PFS as deﬁ ned by the investigators in 
the trials, which included patients across a wide time 
range, but the consistency of the results across the 
meta-analyses is reassuring. The potential gain in the 
use of PFS as a surrogate in locally advanced lung 
cancer is probably smaller than that associated with the 
use of DFS to assess adjuvant treatment because the 
times from progression to death are shorter. The 
possible gains of using PFS should, therefore, be 
weighed against the possible risks and the known biases 
associated with assessing progression21 and the 
diﬃ  culties in assessing local relapses after chemotherapy 
or chemoradiation. 
Use of a similar approach to assess individual patients’ 
data has shown that DFS is useful as a surrogate for 
overall survival in the testing of adjuvant chemotherapy 
regimens for other cancer types, such as colorectal 
cancer, trial-level R²=0·85 (very good).17 The data for 
PFS, however, have been less consistent, although 
excellent correlation (R²=0·98) was seen with overall 
survival in assessment of ﬂ uoropyrimidine-based 
chemotherapy in advanced colorectal cancer.22 A 
combined DFS and PFS endpoint proved to be an 
appropriate surrogate for the assessment of various 
chemotherapy (R²=0·87) and radiotherapy (R²=0·96) 
regimens in locally advanced head and neck cancers.18 
PFS alone, however, was not a valid surrogate for overall 
survival in trials comparing an anthracycline with a 
taxane for advanced breast cancer (R²=0·23).23 Few 
surrogacy assessments based on individual patient data 
have been done in lung cancer. In advanced NSCLC, 
treatment eﬀ ects on PFS were moderately correlated 
with those on overall survival in trials comparing ﬁ rst-
line docetaxel with vinorelbine (R²=0·38).24 In three 
trials of patients with extensive SCLC, PFS was strongly 
associated with overall survival at the trial level 
(R²=0·79).25 Part of the discrepancy between the NSCLC 
and SCLC results could be due to the administration of 
subsequent lines of therapy that prolong survival in 
patients with NSCLCs.
Interpretation of outcomes on the basis of surrogate 
endpoints has several limitations. A surrogate endpoint 
can only be validated for the therapies assessed; 
extrapolation to treatments administered by diﬀ erent 
methods or with substantially diﬀ erent mechanisms of 
action might not be warranted. For instance, for targeted 
agents, surrogate endpoints will need to be studied 
directly in trials of the agents. Additionally, we reassessed 
data from a generation of trials in which chemotherapy 
or radiotherapy were the main treatments being 
investigated and when few, if any, active agents were 
Figure 4: Correlation between treatment eﬀ ects on progression-free and 
overall survival in locally advanced disease
(A) Radiotherapy plus concurrent chemotherapy compared with radiotherapy 
alone in non-small-cell lung cancer. (B) Modiﬁ ed radiotherapy compared with 
standard radiotherapy in non-small-cell and small-cell lung cancers. Correlation 
values are excellent (R2=0·97 and R2=0·96).
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available as subsequent lines of treatment. The use of 
subsequent treatments can be an important confounding 
factor to the eﬀ ectiveness of surrogate endpoints. Also, 
crossover can aﬀ ect the power of assessing eﬀ ects on 
overall survival, particularly when an eﬀ ective second-
line treatment is available.26,27 
The use of DFS or PFS as primary endpoints in future 
clinical trials does not reduce the need for long-term 
follow-up of patients. In many cases it remains necessary 
to con trol for unexpected adverse reactions and to assess 
overall survival, even when crossover to the experimental 
therapy from the control arm is permitted. We stress that 
overall survival remains the most valid available 
endpoint. The use of validated surrogates, however, 
would enable earlier assessments of treatment eﬀ ects 
and could lead to conditional approval by regulatory 
authorities without prema ture discontinuation of follow-
up, which is partic ularly important to assess the potential 
for long-term late or toxic eﬀ ects when a proportion of 
patients are cured.28
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Figure 5: Internal validation of the prediction of overall survival by treatment eﬀ ects on surrogate endpoints
(A) Treatment eﬀ ects on disease-free survival for adjuvant chemotherapy compared with no chemotherapy in non-small-cell lung cancer. (B) Treatment eﬀ ects on progression-free survival eﬀ ects for 
radiotherapy plus concurrent chemotherapy compared with radiotherapy alone in non-small-cell lung cancer. (C) Treatment eﬀ ects on disease-free survival for radiotherapy plus adjuvant 
chemotherapy compared with radiotherapy alone in non-small-cell lung cancer. (D) Treatment eﬀ ects on progression-free survival for modiﬁ ed radiotherapy compared with standard radiotherapy in 
non-small-cell and small-cell lung cancers. Predicted HRs for overall survival are calculated from the observed HR on disease-free or progression-free survival of that particular trial and the surrogate 
model built on all the other trials. Observed HRs are shown for overall survival. All values are shown with 95% prediction intervals. HR=hazard ratio.
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 Panel: Research in context
Systematic review
The gold standard endpoint in randomised clinical trials of lung cancer is overall survival 
because it is simple to measure, easy to interpret, and measurement is unbiased. Some of 
the disadvantages of this endpoint are the need for long-term follow-up and large numbers 
of patients, the eﬀ ect of successive treatment lines that might prolong survival, and the risk 
of non-cancer deaths rising with increasing time. Use of a surrogate endpoint at an earlier 
stage in clinical trials would speed up assessment of treatments and might reduce the cost 
of drug development. We have analysed trial data from ﬁ ve meta-analyses of individual 
patients’ data by the NSCLC Meta-analyses Collaborative Group10–13 and from one by the 
MAR-LC Collaborative Group14 to assess the use of disease-free survival, progression-free 
survival, and locoregional control as surrogate endpoints for overall survival. 
Interpretation
Disease-free survival may be used as a primary endpoint in adjuvant chemotherapy trials 
involving patients with non-small-cell lung cancers, and progression-free survival is suitable 
for use in trials of chemotherapy and radiotherapy in patients with locally advanced lung 
cancer. When progression-free survival is substituted for overall survival, a trade-oﬀ  is found 
between earlier results and possible biases in the assessment of progressions. These results 
do not automatically translate to targeted agents.
